MX2024008477A - Derivados biciclicos de ftalazina-1(2h)-ona y usos relacionados. - Google Patents
Derivados biciclicos de ftalazina-1(2h)-ona y usos relacionados.Info
- Publication number
- MX2024008477A MX2024008477A MX2024008477A MX2024008477A MX2024008477A MX 2024008477 A MX2024008477 A MX 2024008477A MX 2024008477 A MX2024008477 A MX 2024008477A MX 2024008477 A MX2024008477 A MX 2024008477A MX 2024008477 A MX2024008477 A MX 2024008477A
- Authority
- MX
- Mexico
- Prior art keywords
- phthalazine
- inhibiting
- methods
- related uses
- bicyclic derivatives
- Prior art date
Links
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 title 1
- 108010034143 Inflammasomes Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000011594 Autoinflammatory disease Diseases 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 102000039996 IL-1 family Human genes 0.000 abstract 1
- 108091069196 IL-1 family Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263297444P | 2022-01-07 | 2022-01-07 | |
| PCT/US2023/010314 WO2023133271A1 (en) | 2022-01-07 | 2023-01-06 | Bicyclic phthalazin-1(2h)-one derivatives and related uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008477A true MX2024008477A (es) | 2024-08-30 |
Family
ID=85239129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008477A MX2024008477A (es) | 2022-01-07 | 2023-01-06 | Derivados biciclicos de ftalazina-1(2h)-ona y usos relacionados. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250066369A1 (https=) |
| EP (1) | EP4460505A1 (https=) |
| JP (1) | JP2025504374A (https=) |
| KR (1) | KR20240145992A (https=) |
| CN (1) | CN118922421A (https=) |
| AU (1) | AU2023205048A1 (https=) |
| CA (1) | CA3247232A1 (https=) |
| IL (1) | IL314035A (https=) |
| MX (1) | MX2024008477A (https=) |
| WO (1) | WO2023133271A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025153532A1 (en) * | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| RU2364597C1 (ru) * | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ |
| CN116194445A (zh) * | 2020-09-24 | 2023-05-30 | 詹森药业有限公司 | 新化合物 |
-
2023
- 2023-01-06 CN CN202380025701.8A patent/CN118922421A/zh active Pending
- 2023-01-06 WO PCT/US2023/010314 patent/WO2023133271A1/en not_active Ceased
- 2023-01-06 EP EP23705320.2A patent/EP4460505A1/en active Pending
- 2023-01-06 IL IL314035A patent/IL314035A/en unknown
- 2023-01-06 MX MX2024008477A patent/MX2024008477A/es unknown
- 2023-01-06 US US18/726,919 patent/US20250066369A1/en active Pending
- 2023-01-06 KR KR1020247026276A patent/KR20240145992A/ko active Pending
- 2023-01-06 AU AU2023205048A patent/AU2023205048A1/en active Pending
- 2023-01-06 CA CA3247232A patent/CA3247232A1/en active Pending
- 2023-01-06 JP JP2024540866A patent/JP2025504374A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3247232A1 (en) | 2023-07-13 |
| US20250066369A1 (en) | 2025-02-27 |
| IL314035A (en) | 2024-09-01 |
| WO2023133271A1 (en) | 2023-07-13 |
| CN118922421A (zh) | 2024-11-08 |
| KR20240145992A (ko) | 2024-10-07 |
| JP2025504374A (ja) | 2025-02-12 |
| AU2023205048A1 (en) | 2024-07-18 |
| EP4460505A1 (en) | 2024-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002686A (es) | Derivados de sulfamoil urea que contienen una porcion alquil-oxacicloalquilo y usos de los mismos. | |
| EA201992152A1 (ru) | Химические соединения | |
| JOP20230241A1 (ar) | مركبات بيريدازين لتثبيط nlrp3 | |
| MX2025011899A (es) | Compuestos de pirido[4,3-d]pirimidina | |
| JOP20220247A1 (ar) | مثبطات كرومينون تفارغية لفوسفوينوسيتيد 3 كيناز (pi3k) لعلاج أمراض مرتبطة بتعديل p13k | |
| PE20242113A1 (es) | Compuestos de quinolina como inhibidores de kras | |
| MX2024002425A (es) | Compuestos tricíclicos sustituidos como inhibidores de parp y uso de estos. | |
| MX2021011389A (es) | Compuestos de imidazolonilquinolina y usos terapeuticos de los mismos. | |
| MX2023013080A (es) | Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades. | |
| MX2023013082A (es) | Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades. | |
| NO20063693L (no) | Forbindelse og metode for anvendelse | |
| MX2024000234A (es) | Inhibidores del inflamasoma nlrp3. | |
| SA523451700B1 (ar) | (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان | |
| NO20092529L (no) | Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese | |
| ATE370138T1 (de) | Neue imidazopyridine und ihre verwendung | |
| BR0314392A (pt) | Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação | |
| EA030558B1 (ru) | Применение производных пиразолопиридина для лечения рака мочевого пузыря | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| WO2014083327A1 (en) | Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy | |
| ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| MX2024013178A (es) | Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| EP4620533A3 (en) | Antagonist compounds | |
| EA202190323A1 (ru) | ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk | |
| MX2024008477A (es) | Derivados biciclicos de ftalazina-1(2h)-ona y usos relacionados. |